Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Small Lymphocytic Lymphoma
• T-cell Leukemia Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Status: TERMINATED